The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 39 new drug formulations under the Drugs (Price Control) Order (DPCO), 2013, through a gazette notification issued by the Ministry of Chemicals. The prices are applicable exclusive of GST, and manufacturers will not be permitted to market these formulations above the notified retail prices.
The notification covers medicines prescribed for hypertension, cardiovascular disorders, diabetes, bacterial infections, epilepsy, eye disorders, pain management, HIV and certain cancers.
Among the notified prices, Amlodipine, Telmisartan, and Metoprolol Succinate (Extended Release) tablets have been fixed at Rs 12.03 per tablet. Amoxicillin and Potassium Clavulanate dispersible tablets (400mg/57mg) have been priced at Rs 27.31 per tablet.
For cardiovascular patients, Aspirin, Atorvastatin and Clopidogrel capsules have been fixed at Rs 8.86 per capsule. Imatinib oral solution, used in treating chronic myeloid leukaemia, has been priced at Rs 59.61 per ml.
The Darunavir, Ritonavir and Dolutegravir Combination Kit for HIV antiretroviral therapy has been fixed at Rs 330.40 per kit. Among high-value formulations, Tenecteplase injection 50 mg, a thrombolytic agent used in emergency treatment of acute myocardial infarction, has been notified at Rs 60,238.27 per vial.
Compliance Requirements
Manufacturers are required to issue revised price lists through the Integrated Pharmaceutical Database Management System (IPDMS) and furnish copies to State Drug Controllers and dealers. Retailers and distributors must display updated price lists at their premises. The NPPA has warned that non-compliant manufacturers will be liable to deposit the overcharged amounts, along with applicable interest, under the Essential Commodities Act, 1955. |
